Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARS extend: long-term safety extension of apraglutide in short bowel syndrome
2023-510389-28-00Phase 3Authorised
- Sponsor
- VectivBio
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of apraglutide in short bowel syndrome (SBS), sponsored by VectivBio. Primary endpoints: Adverse events, Clinically relevant adverse events of special interest and 3 more. Planned start Jul 2024; status: authorised.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2023-510389-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510389-28-00.